Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as patients without an EGFR mutation. We show that EGFR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Eric, McGlinchey, Kelly, Wang, Jixin, Martin, Philip, Ching, Steven L.K., Floc’h, Nicolas, Kurasawa, James, Starrett, Jacqueline H., Lazdun, Yelena, Wetzel, Leslie, Nuttall, Barrett, Ng, Felicia S.L., Coffman, Karen T., Smith, Paul D., Politi, Katerina, Cooper, Zachary A., Streicher, Katie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855814/
https://www.ncbi.nlm.nih.gov/pubmed/35132961
http://dx.doi.org/10.1172/jci.insight.142843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855814/
https://www.ncbi.nlm.nih.gov/pubmed/35132961
http://dx.doi.org/10.1172/jci.insight.142843

Ejemplares similares